Skip to content

Clinical trials

Completed Coronary Artery Disease trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Coronary Artery Disease Phase: Not applicable Status: Completed Clear all

849 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20011
20029
20038
200411
200518
200624
200726
200834
200936
201040
201148
201246
201349
201451
201552
201650
201744
201845
201951
202037
202142
202245
202336
202421
202511
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed849

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Abbott Medical Devices25
Medtronic Vascular22
Boston Scientific Corporation15
Insel Gruppe AG, University Hospital Bern13
Ottawa Heart Institute Research Corporation11
Elixir Medical Corporation10
University of Edinburgh10
Riphah International University9
Johns Hopkins University8
China National Center for Cardiovascular Diseases7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Coronary Artery Disease849
Myocardial Ischemia69
Myocardial Infarction64
Cardiovascular Diseases51
Coronary Disease49
Coronary Stenosis37
Diabetes Mellitus36
Atherosclerosis31
Acute Coronary Syndrome30
Heart Diseases30

Trials

Showing 1 to 25 of 849. Each trial links to its page on Pharma Observatory.

749 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.